Jacqueline C. Barrientos, MD, associate professor of the Karches Center for Oncology Research at the Feinstein Institute for Medical Research, discusses which types of patients with chronic lymphocytic leukemia are the best candidates for treatment with ibrutinib
Jacqueline C. Barrientos, MD, associate professor of the Karches Center for Oncology Research at the Feinstein Institute for Medical Research, discusses which types of patients with chronic lymphocytic leukemia (CLL) are the best candidates for treatment with ibrutinib (Imbruvica).
Barrientos recommends that younger patients with CLL should receive ibrutinib as part of a combination regimen to help them achieve an earlier and more complete response. On the other hand, she suggests that older patients (over the age of 65 years) should receive ibrutinib monotherapy, as it is a continuous treatment.
Although patients with high-risk CLL have demonstrated encouraging responses from treatment with ibrutinib, these patients may benefit more from an ibrutinib-based combination regimen in the hopes that they could eventually stop receiving treatment. For example, patients with a 17p deletion are more likely to have an earlier relapse than patients with other high-risk cytogenetics while receiving treatment with ibrutinib. A combination approach could help to delay the patient’s relapse, and Barrientos highlights that there are a number of ongoing clinical trials investigating ibrutinib as a part of a combination regimen for high-risk patients.
Novel Approaches Focus on Limiting Toxicity in Older Patients With ALL
April 22nd 2024The major challenges for clinicians treating older patients with acute lymphoblastic leukemia surround the emergence of resistance to existing therapies and the toxicities associated with current chemotherapies.
Read More
Considering the Durability of Zanubrutinib in Relapsed/Refractory CLL
April 11th 2024During a Case-Based Roundtable® event, Marc S. Hoffmann, MD, discussed his viewpoints on the use of Bruton tyrosine kinase inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia and the efficacy behind zanubrutinib in the second article of a 2-part series.
Read More